Fda Approves Lynparza For High Risk Breast Cancer Patients
According to the FDA, approval was based on findings from the OlympiA phase 3 trial—a randomized, placebo-controlled and international study of 1,836 patients with high-risk early breast cancer who completed local treatment and chemotherapy. Patients were randomly tasked to either take 300 mg of Lynparza tablets by mouth twice a day for 1 year or a placebo. The study, which was published in the New England Journal of Medicine, found those who took Lynparza showed a 42% improvement in invasive disease-free survival versus the placebo group....